Milla Pharmaceuticals Announces Approval and Launch of a Generic Version of Sodium Acetate Injection 2MEQ/mL by Pfizer Inc.

Sodium Acetate

MINNETONKA, Minn.--(BUSINESS WIRE)--Milla Pharmaceuticals, a subsidiary of the Alter Pharma Group, announced that it has received abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for its generic version of Sodium Acetate Injection 2MEQ/mL.

As the first approved application, on July 7th, 2021, Milla Pharmaceuticals has established its first commercial sale through its exclusive partner, Woodward Pharma Services LLC, thus securing 180-days of market exclusivity. The FDA has recently listed Sodium Acetate Injection 2MEQ/mL on their FDA Drug Shortages List.

“Woodward Pharma Services LLC is excited to partner with Milla Pharmaceuticals to offer Sodium Acetate as part of Woodward’s growing hospital product portfolio,” said Nirav Patel, President of Woodward Pharma Services LLC.

This achievement marks a milestone for Milla Pharmaceuticals and the Alter Pharma Group not only as their first ANDA approval but also as a first-cycle review approval and garnering FDA’s coveted CGT Exclusivity. “After the launch by Sandoz of our generic injectable acetaminophen (paracetamol IV) in December 2020, being the first Alter Pharma product hitting the US market, this is another important step in our mission to make affordable and high-quality medicines available to all,” commented Filip Van de Vliet, CEO of the Alter Pharma Group, “thereby demonstrating the quite unique capabilities of our R&D and regulatory teams and partners to realize a first-cycle approval.”